Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
Like most functional medicine practices, a large part of our practice involves treating chronic conditions because conventional medicine, for the most part, is concerned solely with symptom relief
For GLP-1s, there is limited evidence supporting doses lower than those studied in clinical trials
Reducing financial friction is essential to converting patients who might otherwise choose compounded alternatives
F.et al (2012)
160,161 For example, HM15211, a triple agonist developed by Hanmi Pharmaceutical in South Korea that activates GLP-1R, GIPR and GCGR has entered early clinical trials for the treatment of obesity and non-alcoholic steatohepatitis (NASH)
Cost and Value Although choosing the least expensive solution is attractive, one should take into account the quality and worth of the good
US$ 27.25
US$ 24.97
US$ 26.79
US$ 24.04
US$ 27.61
US$ 20.46
US$ 20.38
US$ 20.93
US$ 29.51
US$ 20.40
US$ 29.58
